Corcept Therapeutics Inc. achieved positive results from its Phase III study of Corlux for the treatment of Cushing’s Syndrome. The study evaluated the response of two treatment groups: one in patients who were glucose intolerant and one in patients who were hypertensive. Statistically significant improvement in the primary endpoint was achieved in both groups, with 60% responding in the glucose intolerant group and 43% in the hypertensive group. Also, safety data indicates that Corlux was...